TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC

Background: Lung cancer has the highest morbidity and mortality rate among types of malignant tumors, and as such, research into prolonging the survival time of patients is vital. The emergence of immune checkpoint inhibitors (ICIs) has greatly improved the survival of patients with non-small cell l...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuntao, Liu, Yi, Li, Xiaohua, Li, Weiming, Xue, Zhihong, He, Xiaoqian, Xiong, Weijie, He, Lang, Bai, Yifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114764/
https://www.ncbi.nlm.nih.gov/pubmed/35600862
http://dx.doi.org/10.3389/fphar.2022.875149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114764/
https://www.ncbi.nlm.nih.gov/pubmed/35600862
http://dx.doi.org/10.3389/fphar.2022.875149

Ejemplares similares